BACKGROUND: Although airway inflammation plays a major role in the pathophysiology of asthma, quantitative markers of airway inflammation are limited in clinical practice. OBJECTIVE: To determine if levels of noninvasive markers of eosinophil-catalyzed oxidation, lipid peroxidation, and nitric oxide production are associated with asthma. METHODS: Participants were enrolled from academic medical centers participating in the Severe Asthma Research Program. Clinical characteristics, laboratory data, pulmonary function tests, and levels of the following noninvasive markers were obtained: urinary bromotyrosine, a marker of eosinophil-catalyzed oxidation; urinary F(2)-isoprostanes, markers of lipid peroxidation; and exhaled nitric oxide, a marker of airway inflammation RESULTS: Fifty-seven asthmatic participants and thirty-eight healthy participants were enrolled. Bromotyrosine, F(2)-isoprostanes, and exhaled nitric oxide were each significantly increased in asthmatic participants versus controls (p<0.01). An elevated level (greater than median) of any marker was associated with a significant 3- to 6-fold greater odds of having asthma. Participants with two or more elevated marker levels showed an 18-fold greater odds of having asthma. Relationships were also noted with airflow obstruction and bronchodilator response. CONCLUSION: Findings from this pilot study indicate that urinary levels of bromotyrosine and F(2)-isoprostanes, in addition to exhaled nitric oxide levels, are associated with asthma.
BACKGROUND: Although airway inflammation plays a major role in the pathophysiology of asthma, quantitative markers of airway inflammation are limited in clinical practice. OBJECTIVE: To determine if levels of noninvasive markers of eosinophil-catalyzed oxidation, lipid peroxidation, and nitric oxide production are associated with asthma. METHODS:Participants were enrolled from academic medical centers participating in the Severe Asthma Research Program. Clinical characteristics, laboratory data, pulmonary function tests, and levels of the following noninvasive markers were obtained: urinary bromotyrosine, a marker of eosinophil-catalyzed oxidation; urinary F(2)-isoprostanes, markers of lipid peroxidation; and exhaled nitric oxide, a marker of airway inflammation RESULTS: Fifty-seven asthmatic participants and thirty-eight healthy participants were enrolled. Bromotyrosine, F(2)-isoprostanes, and exhaled nitric oxide were each significantly increased in asthmatic participants versus controls (p<0.01). An elevated level (greater than median) of any marker was associated with a significant 3- to 6-fold greater odds of having asthma. Participants with two or more elevated marker levels showed an 18-fold greater odds of having asthma. Relationships were also noted with airflow obstruction and bronchodilator response. CONCLUSION: Findings from this pilot study indicate that urinary levels of bromotyrosine and F(2)-isoprostanes, in addition to exhaled nitric oxide levels, are associated with asthma.
Authors: Wendy C Moore; Eugene R Bleecker; Douglas Curran-Everett; Serpil C Erzurum; Bill T Ameredes; Leonard Bacharier; William J Calhoun; Mario Castro; Kian Fan Chung; Melissa P Clark; Raed A Dweik; Anne M Fitzpatrick; Benjamin Gaston; Mark Hew; Iftikhar Hussain; Nizar N Jarjour; Elliot Israel; Bruce D Levy; James R Murphy; Stephen P Peters; W Gerald Teague; Deborah A Meyers; William W Busse; Sally E Wenzel Journal: J Allergy Clin Immunol Date: 2007-02 Impact factor: 10.793
Authors: J C MacPherson; S A Comhair; S C Erzurum; D F Klein; M F Lipscomb; M S Kavuru; M K Samoszuk; S L Hazen Journal: J Immunol Date: 2001-05-01 Impact factor: 5.422
Authors: S B Khatri; M Ozkan; K McCarthy; D Laskowski; J Hammel; R A Dweik; S C Erzurum Journal: Am J Respir Crit Care Med Date: 2001-11-15 Impact factor: 21.405
Authors: R A Dweik; S A Comhair; B Gaston; F B Thunnissen; C Farver; M J Thomassen; M Kavuru; J Hammel; H M Abu-Soud; S C Erzurum Journal: Proc Natl Acad Sci U S A Date: 2001-02-20 Impact factor: 11.205
Authors: Anne M Fitzpatrick; Benjamin M Gaston; Serpil C Erzurum; W Gerald Teague Journal: J Allergy Clin Immunol Date: 2006-10-10 Impact factor: 10.793
Authors: Dominick E Shaw; Mike A Berry; Mike Thomas; Ruth H Green; Chris E Brightling; Andrew J Wardlaw; Ian D Pavord Journal: Am J Respir Crit Care Med Date: 2007-05-11 Impact factor: 21.405
Authors: Panpicha Sattasathuchana; Naris Thengchaisri; Jan S Suchodolski; Jonathan A Lidbury; Jörg M Steiner Journal: J Vet Diagn Invest Date: 2019-02-15 Impact factor: 1.279
Authors: Zeneng Wang; Joseph A DiDonato; Jennifer Buffa; Suzy A Comhair; Mark A Aronica; Raed A Dweik; Nancy A Lee; James J Lee; Mary Jane Thomassen; Mani Kavuru; Serpil C Erzurum; Stanley L Hazen Journal: J Biol Chem Date: 2016-09-01 Impact factor: 5.157
Authors: Emma K Larkin; Yu-Tang Gao; Tebeb Gebretsadik; Terryl J Hartman; Pingsheng Wu; Wanqing Wen; Gong Yang; Chunxue Bai; Meiling Jin; L Jackson Roberts; Myron Gross; Xiao O Shu; Tina V Hartert Journal: Am J Respir Crit Care Med Date: 2015-01-01 Impact factor: 21.405
Authors: Douglas C Cowan; D Robin Taylor; Laura E Peterson; Jan O Cowan; Rochelle Palmay; Avis Williamson; Jef Hammel; Serpil C Erzurum; Stanley L Hazen; Suzy A A Comhair Journal: J Allergy Clin Immunol Date: 2014-12-06 Impact factor: 10.793
Authors: Jeevan K Prasain; Alireza Arabshahi; Pam R Taub; Scott Sweeney; Ray Moore; J Daniel Sharer; Stephen Barnes Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2012-12-20 Impact factor: 3.205